Back in September of 2010 he was also names to the Board of another technology company that deals with urology and cancer therapies. Since his tenure at the FDA 
it sounds like von Eschenbach is returning to his roots with using his expertise in the clinical area of healthcare. BD
Former FDA Commissioner, Dr. Andrew von Eschenbach Finds a Home on the Board of HistoSonics
Viamet Pharmaceuticals has landed a healthcare heavyweight in naming prostate cancer expert and former U.S. Food and Drug Administration commissioner Dr. Andrew von Eschenbach to the company’s board of directors.
Durham, North Carolina-based Viamet has a proprietary technology that identifies and blocks certain enzyme targets. The technology can be used to develop new drugs and Viamet last year signed a licensing agreement with Novartis (NYSE:NVS) that could be worth more than $200 million if Viamet is able to develop certain enzyme inhibitors for the Swiss drug company.
Cancer expert and former FDA leader von Eschenbach named to Viamet board
![EZClaim[4]](http://lh4.ggpht.com/_v3zjJigoAPE/TG1-9etl5ZI/AAAAAAAAgqg/CRMlet5Pi5k/EZClaim44.png?imgmax=800 "EZClaim[4]")
Math–This Could be a Subject for Michael Moore to Explore and Document In a Movie
Screenings Too–Killer Algorithms Part 12–Medical Billing Codes Style
Assessing Consumer Credit Scores–Attack of the Killer Algorithms Chapter 21 With Flawed Data
Duping” Society Combined With A World of Rogue Algorithms & Flawed Data Continues In Markets As Seen With Knight Capital This Week-Attack of the Killer Algorithms Chapter 36
Study Fraud With EHR Technologies, Namely Medical Records/Billing Software Used by Hospitals– HHS And SEC Continue Getting Their Non-Algorithmic Fannies Kicked–Attack of the Killer Algorithms Chapter 46
SilverScript Senior Drug Program Sanctioned by Medicare Until the Payment And Billing Algorithms are Cleaned Up-Killer Algorithms Chapter 53
